Friday 6 November 2026 Export BMRN’s income statement to Excel — free account

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.

Revenue: +32.0%
EPS: −296.6%
Free cash flow: −52.3%
Total debt: +599.5%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

55.81 0.31 −0.55%

Follow BMRN

Alert me

Market cap: $10.9B
P/E: 0.0×
Fwd P/E: 32.7×
Dividend yield: —
F-score: 5/9
Altman Z: 5.67
Beneish M: −2.49
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

BioMarin Pharmaceutical Inc. (BMRN) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, BioMarin Pharmaceutical Inc. (BMRN) trades at a price to free cash flow of 20.0×. Over the past ten years it has ranged from 0.0× (March 2020) to 7,130× (June 2020); the current reading is higher than 47% of that period. That is below the Biotechnology industry median of 24.8× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/BMRN/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="BioMarin Pharmaceutical Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/BMRN/metrics/price-to-free-cash-flow">BioMarin Pharmaceutical Inc. (BMRN) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	15.9×	(38.22%)
FY2024	25.7×	(92.78%)
FY2023	357×	182.54%
FY2022	126×	44.77%
FY2021	87.2×	(91.75%)
FY2020	1,057×	—
FY2019	0.0×	—
FY2018	298×	(57.26%)
FY2017	697×	—
FY2016	0.0×	—

Period	Price to free cash flow	Change
Sep 2026	21.3×	39.70%
Jun 2026	15.3×	6.60%
Mar 2026	14.3×	(9.89%)
Dec 2025	15.9×	26.22%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 7,130×

Ten-year median 40.4×

Current reading's percentile 47

Company	Price to free cash flow
TWST Twist Bioscience Corporation compare	n/m
IBRX ImmunityBio, Inc. compare	n/m
KYMR Kymera Therapeutics, Inc. compare	n/m
SMMT Summit Therapeutics PLC compare	n/m
PCVX Vaxcyte, Inc. compare	n/m
BMRN BioMarin Pharmaceutical Inc.	20.0×
TECH Bio-Techne Corp compare	43.1×
CAI Caris Life Sciences,�Inc. compare	191×
TGTX TG Therapeutics, Inc. compare	474×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

BioMarin Pharmaceutical Inc. (BMRN) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on BMRN

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on BMRN

Stockrow Weekly